2. Metabolic Enzyme/Protease MAPK/ERK Pathway Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage NF-κB Immunology/Inflammation
  3. Prolyl Endopeptidase (PREP) Drug Metabolite JNK PPAR NF-κB Interleukin Related
  4. Oroxylin A-7-O-glucuronide

Oroxylin A-7-O-glucuronide  (Synonyms: Oroxyloside; Oroxylin A-7-O-β-D-glucuronide)

Cat. No.: HY-N2481 Purity: 99.83%
COA
SDS
Handling Instructions Technical Support

Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities.

For research use only. We do not sell to patients.

Oroxylin A-7-O-glucuronide

Oroxylin A-7-O-glucuronide Chemical Structure

CAS No. : 36948-76-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Oroxylin A-7-O-glucuronide:

Oroxylin A-7-O-glucuronide Related Antibodies

Top Publications Citing Use of Products

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All PPAR Isoform Specific Products:

View All Isoforms
PPARα PPARβ/δ PPARγ PPAR PPARδ

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities[1][2][3][4][5][6].

IC50 & Target[1][2][3][4][5][6]

PPARγ

 

IL-6

 

IL-1β

 

In Vitro

Oroxylin A-7-O-glucuronide (40-160 μM; 24 h) inhibits the viability and invasion ability of EA.hy926 cells[1].
Oroxylin A-7-O-glucuronide (5-100 μM; 24 h) significantly suppresses the glioma cell proliferation in a dose-dependent manner in U87-MG, U251-MG, U138-MG and SHG44 cells, with IC50 values of 36.87, 52.36, 59.67 and 56.39 μM, respectively[2].
Oroxylin A-7-O-glucuronide (100 μM; 24 h) reduces APAP (HY-66005)-induced apoptosis and necroptosis in L02 and AML12 cells by inhibiting JNK pathway[3].
Oroxylin A-7-O-glucuronide (2-100 μM; 24 h) decreases LPS-induced pro-inflammatory cytokines in RAW264.7 and BMDM via PPARγ-mediated NF-κB inhibition[4].
Oroxylin A-7-O-glucuronide (50 μM) reduces H2O2-induced IL-6 production in L02 and LX2 cells through autophagy activation[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Oroxylin A-7-O-glucuronide Related Antibodies

Cell Invasion Assay[1]

Cell Line: EA.hy926
Concentration: 40 μM, 80 μM, 160 μM
Incubation Time: 24 h
Result: Inhibited the migration and invasion of EA.hy926 cells in a concentration-dependent manner, and the inhibitory rates were 10.2%, 48.0% and 73.4%, respectively.

Western Blot Analysis[1]

Cell Line: EA.hy926
Concentration: 40 μM, 80 μM, 160 μM
Incubation Time: 24 h
Result: Reduced phosphorylation of VEGFR2 at pY1214, pY951, pY1175.
In Vivo

Oroxylin A-7-O-glucuronide (40-80 mg/kg; i.v.; every two days) inhibits angiogenesis in Matrigel plug assay and reduces growth of A549 xenografted tumors in nude mice with low toxicity[1].
Oroxylin A-7-O-glucuronide (10-40 mg/kg; p.o.; daily; 4 weeks) suppresses U87-MG xenograft tumor growth in athymic nude mice without affecting body weight and organ function [2].
Oroxylin A-7-O-glucuronide (100 mg/kg; i.g.) ameliorates APAP (HY-66005)-induced hepatotoxicity in C57BL/6 mice by reducing serum ALT/AST and liver inflammation[3].
Oroxylin A-7-O-glucuronide (20-80 mg/kg; p.o.; 10 days) alleviates DSS-induced colitis in C57BL/6 mice by reducing colon damage and pro-inflammatory cytokines [4].
Oroxylin A-7-O-glucuronide (20-80 mg/kg; i.g.; every other day) inhibits CCl4-induced liver fibrosis and DEN (HY-N7434) + CCl4 (HY-Y0298)-induced hepatocarcinogenesis in C57BL/6 and Atg5Hep-/- mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (6-8 weeks old, 18-22 g) with A549 xenografts[1]
Dosage: 40 mg/kg, 80 mg/kg
Administration: Intravenous injection, every two days
Result: Decreased tumor volume and weight.
Reduced microvessel density (CD31 staining) and hemoglobin content in Matrigel plugs.
Decreased pY1214 VEGFR2 and increased R-Ras, VE-cadherin in tumors.
Showed no significant change in body weight or organ damage.
Animal Model: Female C57BL/6 mice (35-40 days old, 18-22 g) with DSS-induced colitis[4]
Dosage: 20 mg/kg, 40 mg/kg, 80 mg/kg
Administration: Intragastric administration, 10 dayss
Result: Attenuated body weight loss, colon shortening and DAI score.
Reduced MPO, iNOS activity and CD11b+ cell infiltration.
Decreased IL-1β, IL-6, TNF-α in serum and colon; up-regulated PPARγ and inhibited NF-κB p65 nuclear translocation.
Molecular Weight

460.39

Formula

C22H20O11
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)=C1OC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (108.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1721 mL 10.8604 mL 21.7207 mL
5 mM 0.4344 mL 2.1721 mL 4.3441 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.83%

SDS (393 KB)

COA (252 KB) HNMR (283 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1721 mL 10.8604 mL 21.7207 mL 54.3018 mL
5 mM 0.4344 mL 2.1721 mL 4.3441 mL 10.8604 mL
10 mM 0.2172 mL 1.0860 mL 2.1721 mL 5.4302 mL
15 mM 0.1448 mL 0.7240 mL 1.4480 mL 3.6201 mL
20 mM 0.1086 mL 0.5430 mL 1.0860 mL 2.7151 mL
25 mM 0.0869 mL 0.4344 mL 0.8688 mL 2.1721 mL
30 mM 0.0724 mL 0.3620 mL 0.7240 mL 1.8101 mL
40 mM 0.0543 mL 0.2715 mL 0.5430 mL 1.3575 mL
50 mM 0.0434 mL 0.2172 mL 0.4344 mL 1.0860 mL
60 mM 0.0362 mL 0.1810 mL 0.3620 mL 0.9050 mL
80 mM 0.0272 mL 0.1358 mL 0.2715 mL 0.6788 mL
100 mM 0.0217 mL 0.1086 mL 0.2172 mL 0.5430 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Oroxylin A-7-O-glucuronide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Oroxylin A-7-O-glucuronide36948-76-2Oroxyloside Oroxylin A-7-O-β-D-glucuronideProlyl Endopeptidase (PREP)Drug MetaboliteJNKPPARNF-κBInterleukin Relatedprolyl oligopeptidasePOPc-Jun N-terminal kinasePeroxisome proliferator-activated receptorsNuclear factor-κBNuclear factor-kappaBILprolyloligopeptidaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Oroxylin A-7-O-glucuronide
Cat. No.:
HY-N2481
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.